The strategy of initiating hypertension treatment with combination versus single-drug therapy was formally tested in a prospective, double-blind, parallel-group trial in blacks with stage 2 hypertension (mean sitting systolic BP (MSSBP) X160 and o200 mm Hg). Participants were randomized equally to amlodipine/valsartan (A/V) (n ¼ 286) or amlodipine (A) monotherapy (n ¼ 286). After 2 weeks, there was forced titration of A/V 5/160 mg to A/V 10/160 mg and of A 5 to A 10 mg followed by 10 additional weeks of treatment. If SBP was X130 mm Hg at week 4, the protocol allowed optional titration of A/V to the 10/320 mg dose and, at week 8, hydrochlorothiazide 12.5 mg was optionally added to both A/V and A if SBP X130 mm Hg. Amlodipine/ valsartan at week 8 lowered MSSBP last observation carried forward significantly4A (33.3 vs 26.6 mm Hg, Po0.0001). Lowering of MSSBP with A/V significantly exceeded that of A in several specified subgroups-the elderly (X65 years), isolated systolic hypertension, and those with body mass index (BMI) X30 kg/m 2 . More patients treated with A/V than A achieved BP control (o140/90 mm Hg) both at weeks 8 (49.8 vs 30.2%; Po0.0001) and 12 (57.2 vs 35.9%; Po0.0001). Both treatment regimens were well tolerated. In conclusion, the strategy of initiating combination antihypertensive drug therapy in blacks with stage 2 hypertension with amlodipine /valsartan achieves greater and quicker reductions in BP as well as significantly higher BP control rates than starting treatment with amlodipine monotherapy.
Introduction
Adult blacks in the United States have the highest age-adjusted rates of hypertension prevalence 39.1% (vs 28.5% in whites and 27.8% in Mexicans). 1 Compared with whites, blacks also have an earlier onset of hypertension, more extreme elevations of blood pressure (BP) once hypertensive, greater pressure-related target-organ damage (for example, left ventricular hypertrophy) and excess morbid and fatal cardiovascular events including stroke, coronary heart disease, heart failure and chronic kidney disease (CKD)/end-stage renal disease. [2] [3] [4] The underlying mechanism(s) for the excess of hypertension burden in blacks is only partially understood. Physiologic and genetic factors as well as sustained environmental exposures have all been proposed. Physiologic factors include excess obesity, more salt sensitivity, higher vascular resistance, endothelium-dependent and independent vascular dysfunction, greater arteriolar remodelling and, despite a tendency toward lower circulating renin activity, greater activation of the local renin-angiotensin-aldosterone system compared with whites. [5] [6] [7] [8] [9] There is also a lesser nocturnal decline in BP (non-dipping) and therefore higher nocturnal BP levels in blacks compared with whites. 10, 11 Sustained environmental exposureshigh dietary sodium and low dietary potassium and possibly calcium intakes-as well obesity, diabetes and CKD all plausibly contribute to both elevated BP levels as well as to the abnormal diurnal variation in BP.
Black hypertensives less often attain their BP goals than whites despite having higher rates of hypertension awareness and pharmacological treatment than whites. 12, 13 Calcium antagonists and diuretics have long been preferred as an antihypertensive therapy in blacks, especially relative to renin-angiotensin system (RAS) and beta blockers, because of their greater average reductions in BP. 14, 15 The presence of high pretreatment BP levels as well concurrent obesity, diabetes, salt sensitivity, albuminuria/proteinuria and depressed levels of kidney function in blacks, all portend resistance to antihypertensive drug treatment necessitating greater intensity of treatment for attainment of BP control as well as a slower attainment of goal BP. 16, 17 Therefore, not surprisingly, the majority of blacks, especially those with higher pretreatment BP levels and/or with co-morbidities such as diabetes and CKD/albuminuria, remain above target BP levels when treated with single antihypertensive agents. Thus, the rationale for the International Society on Hypertension in Blacks to recommend strong consideration of combination drug therapy if BP is 415/ 10 mm Hg above goal. 3 The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) also recommended consideration of combination therapy when the BP is X20/10 mm Hg above goal levels. 2 The drug classes most commonly used in single-pill combinations of antihypertensive agents, in large part because they potently lower BP, are a diuretic or calcium channel blocker (CCB) plus a RAS-blocking agent. 3 Until recently, the highly effective BP-lowering single-pill combinations utilizing RAS blockers with either a diuretic or calcium antagonist have all contained angiotensin-converting enzyme (ACE) inhibitors. However, angioedema rates with ACE inhibitors are B 4-fold higher in blacks than in whites. 15, 18 Therefore we undertook this study (EXforge evaluation in Stage Two hypertensives of AfricaN Descent) to compare the BP-lowering efficacy, safety and tolerability of combination antihypertensive drug therapy with amlodipine/valsartan, a new combination that includes an angiotensin receptor blocker instead of an ACE inhibitor with a calcium antagonist, compared to monotherapy with amlodipine, a calcium antagonist, a long favored drug class in hypertensive blacks. This study provided a unique opportunity to quantify the magnitude of differences, especially in regards to BP response and control, both before and after add-on antihypertensive therapy with hydrocholorthiazide, in a highrisk hypertensive population of whom the majority would ultimately require more than one drug to achieve and maintain BP below goal levels.
Materials and methods
The study was conducted in black male and female outpatients 18 years of age with stage 2 hypertension, defined as mean sitting systolic BP (MSSBP) X160 and o200 mm Hg at randomization. The study was conducted at 74 centres in the USA, South Africa, Colombia and Ecuador. Ethics Committee and/or Institutional Review Board approval was granted at all participating centres, and all patients gave written informed consent prior to enrollment. The study was conducted in accordance with the ethical principles of the current Declaration of Helsinki.
Enrolled patients could be either untreated or uncontrolled and taking 1 or 2 antihypertensive medications. Race/ethnicity was determined by patient self-identification. Patients with MSSBP X200 mm Hg and/or a mean sitting diastolic BP (MSDBP) X120 mm Hg were excluded. In addition, those with uncontrolled hypertension despite treatment (MSSBP X140 and o180 mm Hg taking more than two antihypertensive medications or MSSBP X180 mm Hg taking more than one medication), and those with controlled hypertension (MSSBP o140 mm Hg) taking more than three antihypertensive medication were excluded. Patients were also excluded if they had malignant or secondary hypertension; hypertensive encephalopathy, a history of cardiac or cerebrovascular disease or event, evidence of hepatic, pancreatic or renal impairment and type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus. Among the other exclusion criteria were gastrointestinal disease or gastrointestinal surgery that might interfere with drug absorption. Patients could not participate if they had a history of drug or alcohol abuse within the past 2 years. Women who were pregnant, nursing, or of child-bearing potential and not using an acceptable method of contraception were also excluded.
Study design
This study was a 12-week, randomized, doubleblind, parallel-group, active-controlled, multicentre clinical trial (Figure 1 ). Following a 3-to 7-day washout period, eligible patients were randomized and subsequently received combination therapy with amlodipine/valsartan or amlodipine monotherapy. Patients randomized to combination therapy received amlodipine 5 mg/valsartan 160 mg for 2 weeks followed by forced titration to amlodipine 10 mg/valsartan 160 mg for the remaining 10 weeks, whereas those on amlodipine monotherapy received 2 weeks of amlodipine 5 mg followed by 10 weeks of amlodipine 10 mg. Valsartan could be optionally titrated to 320 mg if MSSBP was X130 mm Hg at week 4 in patients randomized to combination therapy. After 8 weeks, regardless of the assigned treatment, patients with MSSBP X130 mm Hg were allowed to have optional open-label hydrochlorothiazide (HCTZ) 12.5 mg added to therapy. Study drugs, together with matching placebo (where applicable), were taken once daily in the morning, except on days of a study visit so that BP could be measured at trough (24 ± 3 h following the last dose of study medication). Concomitant administration of drugs likely to affect BP, as well as those likely to interact with study medication, was prohibited throughout the study.
Efficacy assessments
Office BP measurements were made using an Omron BP monitor in accordance with the guidelines of the British Hypertension Society. 19 Sitting and standing BP and sitting pulse rate were measured at each visit. For sitting BP, patients rested for a minimum of 5 min before any measurements were taken. Three replicate BP measurements were obtained at least 2-3 min apart, and the mean of these three measurements was used as average sitting BP. Standing BP was measured only once, within 2 min after the last sitting BP measurement. Self-measured blood pressure (SMBP) was allowed to aid patients and investigators in identifying emergent hypertensive situations throughout the study, however, SMBP information was not recorded for analysis. The primary efficacy outcome was change in MSSBP from baseline to week 8 (pre-HCTZ treatment) applying last observation carried forward in case of a missing MSSBP value at week 8. Secondary efficacy variables were change in MSDBP from baseline to week 8; change from baseline in MSSBP and MSDBP after 2, 4, 8 and 12 weeks of treatment; and the proportion of patients achieving overall BP control (o140/90 mm Hg) after 12 weeks of treatment. Prospective exploratory analyses were conducted to compare the combination of amlodipine/ valsartan with amlodipine monotherapy in the proportion of patients reaching diastolic BP control (MSDBP o90 mm Hg) after 2, 4, 8 and 12 weeks of treatment; and overall BP control rate (MSSBP/ MSDBP o140/90 mm Hg) at weeks 2, 4 and 8. A prespecified subgroup analysis using baseline MSSBP (X180 mm Hg) was also performed for the secondary efficacy variables.
Safety measurement
Safety was assessed in all randomized patients who received at least one dose of the double-blind study drug. Safety assessments consisted of the regular monitoring and recording of all adverse events and serious adverse events, physical examination, vital signs and laboratory evaluations. The incidence of self-reported oedema and peripheral oedema, as well as other adverse events related to study medication was summarized.
Statistical analyses
A sample size of 518 patients was required for at least 85% power to detect difference in change from baseline in MSSBP between the two treatment groups. A s.d. of 14 mm Hg and a between-group difference of 3.7 mm Hg was assumed, based on the results of a previous study 20 that compared the combination of amlodipine/valsartan with amlodipine monotherapy for 8 weeks. A two-sided t-test with a significance level of 0.05 was applied. A total sample size of 558 participants was required to ensure a projected 7% discontinuation rate. The intent-to-treat population was defined as all randomized patients who had a baseline BP measurement and at least one post-baseline efficacy assessment. The safety population was defined as all patients who received at least one dose of the double-blind study medication after randomization.
The primary efficacy variable (change in MSSBP from baseline to week 8 LOCF) was analysed using the analysis of covariance (ANCOVA). Treatment, country, and length of washout were factors in the model, and baseline MSSBP was fitted as a Amlodipine/valsartan in blacks with stage 2 hypertension JM Flack et al covariate. Least squares mean changes in MSSBP, the between-treatment group difference between these changes, and the associated two-sided 95% confidence interval (CI) were calculated. Week 8 LOCF was defined as the week 8 value or the last documented post-dose value. The null hypothesis was rejected when the 2-sided P-value was o0.05.
Change from baseline in MSDBP at week 8 LOCF and change from baseline in MSSBP and MSDBP at weeks 2, 4, 8 and 12 were analysed separately using the same model as for the primary analysis (baseline MSDBP used as covariate in an analysis model for change from baseline in MSDBP). Unadjusted control rates were expressed as percentages with the corresponding two-sided asymptotic 95% CI. The proportion of patients achieving overall BP control was analysed using a logistic regression model, with treatment and length of washout as fixed factors and baseline MSSBP and MSDBP as covariates. The odds ratio and corresponding 95% CI were also calculated. Subgroup analyses were conducted for the systolic BP control and MSSBP reduction from baseline stratifying by age, gender, Hispanic ethnicity, diabetes status, body mass index and isolated systolic hypertension. The findings observed are presented for particular subgroups of interest-the elderly (X65 years), men and women, those with isolated systolic hypertension, persons with diabetes, obese patients-body mass index X30 kg/m 2 and patients of Hispanic origin.
Post hoc analyses were performed for pulse pressure, urinary albumin-to-creatinine ratio (UACR), and primary and secondary variables by various subgroups. Change from baseline in pulse pressure was analysed at weeks 2, 4, 8 and 12 using ANCOVA. Treatment, country and length of washout were factors and baseline pulse pressure was a covariate. Change from baseline in UACR was analysed using ANCOVA with treatment, country and length of washout as factors and baseline (log) UACR as covariate. Analysis was based on logtransformed data and back-transformed results were calculated. The proportion of patients who achieved normalization at week 12 (UACR o30 mg g À1 ) was calculated. The incidence of peripheral oedema was analysed by logistic regression with treatment, sex and age category as factors.
Results

Patient disposition and baseline characteristics
Patient disposition is illustrated in Figure 2 . A total of 1042 black patients from South America, South Africa, and the United States entered the screening phase of the study; of these, 572 were randomized to receive either amlodipine/valsartan tablets (n ¼ 286) or amlodipine/placebo tablets (n ¼ 286). The majority of randomized patients were from the United States (n ¼ 401), followed by South Africa (n ¼ 85), Colombia (n ¼ 53), and Ecuador (n ¼ 33). A total of 497 (86.9% of randomized patients) completed the double-blind treatment. Similar numbers of patients discontinued prematurely in the amlodipine/valsartan (n ¼ 39, 13.6%) and the amlodipine (n ¼ 36, 12.6%) treatment groups. The most frequent reasons for participant discontinuation were loss to follow-up, withdrawal of consent, adverse events and protocol deviations. Table 1 ). The average age was 53.2 years and 60% (344 patients) were women with the majority of patients o65 years of age (83%). Ninety-five patients (17%) were also of Hispanic origin. Overall, 81 patients (14%) had severe hypertension (MSSBP X180 mm Hg) and 88 patients (15%) had diabetes. At baseline, the mean sitting BP was 170.5/ 98.3 mm Hg.
Drug exposure was similar in the two treatment groups; mean duration of exposure to amlodipine/ valsartan was 11.1 (s.d. 3.1) weeks and to amlodipine, 11.3 (s.d. 2.8) weeks. At week 4, 181 patients (63.3%) were up-titrated to valsartan 320 mg in the combination therapy group and 213 patients (74.7%) in the amlodipine monotherapy group received sham up-titration. At week 8, 147 patients (51.4%) in the amlodipine/valsartan group and 185 patients (64.9%) in the amlodipine monotherapy group were optionally titrated to receive once-daily HCTZ 12.5 mg.
Efficacy
The primary efficacy parameter was change in MSSBP from baseline to week 8 LOCF. Patients who received the combination regimen of amlodipine/valsartan had a significantly greater reduction from baseline in MSSBP at week 8 (LOCF) than those who received amlodipine monotherapy (33.3 vs 26.6 mm Hg; 95% CI for the difference, 4.1-9.1; Po0.0001) (Figure 3) .
Significantly greater reductions from baseline in MSSBP were seen as early as week 2 in the amlodipine and valsartan combination group compared with amlodipine monotherapy, and continued throughout the study (Figure 4) . Amlodipine/valsartan also produced significantly greater reductions in MSDBP change from baseline compared with amlodipine alone throughout the study: week 2 (9.7 vs 6.9 mm Hg; 95% CI for the difference, 1.4 to 4.1; P ¼ 0.0001), week 4 (13.2 vs 10.7 mm Hg; 95% CI for the difference, 1.0 to 3.9; P ¼ 0.0008), week 8 (14.0 vs 11.2 mm Hg; 95% CI for the difference, 1.4 to 4.3; P ¼ 0.0002), week 8 LOCF (13.6 vs 10.8; 95% CI, 1.3 to 4.2; P ¼ 0.0002), and week 12 (16.1 vs 12.8 mm Hg; 95% CI for the difference, 1.9 to 4.9; Po0.0001). The rates of BP control (o140/90 mm Hg) were significantly higher in patients randomized to the combination of amlodipine/valsartan than to amlodipine alone. At week 8, 49.8% of patients in the combination therapy group and 30.2% in the monotherapy group had their BP controlled to o140/90 mm Hg (odds ratio 2.4; 95% CI, 1.6 to 3.4; Po0.0001). At week 12, after the optional addition of HCTZ, 57.2% of patients in the combination therapy group and 35.9% in the monotherapy group attained BP o140/ 90 mm Hg (odds ratio 2.5; 95% CI, 1.7 to 3.6; Po0.0001).
Additional analyses
Combination therapy with amlodipine/valsartan produced greater reductions in MSSBP change from baseline to week 8 than amlodipine monotherapy in all patient subgroups analysed ( Figure 5 ), however, only in patients aged X65 years, patients with isolated systolic hypertension, and obese patients (body mass index X30 kg/m 2 ) did these differences n is the number of ITT patients with both baseline and endpoint non-missing values. Error bars denote s.e.m. P-value refers to comparison of monotherapy with combination therapy 95% CI, (-9.1, -4.1). CI = confidence interval. Compared with amlodipine monotherapy, the combination of amlodipine/valsartan produced a significantly greater MSSBP reduction from baseline in mean sitting pulse pressure in both older (X65 years) and younger (o65 years) participants at week 8, with a greater between-group difference seen in the older compared with the younger subgroup (8.2 vs 2.9 mm Hg, respectively) ( Figure 7) .
At week 8, HCTZ could be added to the treatment regimen in patients who had not reached the SBP target (MSSBP o130 mm Hg). In analyses restricted to those patients receiving add-on, optional HCTZ, those in the amlodipine/valsartan combination group experienced greater reductions in MSSBP between weeks 8 and 12 compared with those in the amlodipine monotherapy group (8.5 (s.e.m. 1.6) mm Hg vs 4.6 (s.e.m. 1.4) mm Hg, respectively).
A post hoc analysis of urinary UACR was determined by the collection of clean catch, midstream urine samples collected at baseline and at week 12 (end of study). A total of 157 patients in the amlodipine/valsartan combination therapy group and 160 patients in the amlodipine monotherapy group had UACR measurements recorded at both baseline and week 12. At week 12, the amlodipine/ valsartan combination group had a 30% reduction from baseline in UACR vs a 10% increase in the amlodipine monotherapy group.
Safety and tolerability
Adverse events were reported in 44.8% of the 571 patients in the safety population, out of whom, 44.4% received combination of amlodipine/valsartan and 45.3% received amlodipine monotherapy. The most common adverse events occurring in X2% of patients in either treatment group are listed in Table 2 . Most adverse events in both treatment groups were mild-to-moderate in severity and were not related to the study drug. Serious adverse events were reported in three (1.0%) patients in the amlodipine/valsartan group. These included transient ischaemic attack, hypersensitivity, and intervertebral disc protrusion. In the amlodipine group, three (1.1%) patients reported serious adverse events. These included renal failure, cholangitis and chest pain. Overall study drug discontinuations due to adverse events occurred more frequently in the amlodipine monotherapy group than in the amlodipine/valsartan combination therapy group n is the number of ITT patients. Data is represented as least square mean (LSM) changes ±s.e.m. P-value refers to comparison of monotherapy with combination therapy Figure 7 Change in mean sitting pulse pressure (mm Hg) from baseline to week 8 by treatment strategy and age category in black patients with stage 2 hypertension (intent-to-treat population). CI, confidence interval. (9 (3.1%) vs 7 (2.4%), respectively). No deaths were reported. Although peripheral oedema occurred more frequently in the amlodipine/valsartan group (12.6%) than in the amlodipine monotherapy group (9.5%), the difference was neither statistically significant (P ¼ 0.15) nor clinically relevant.
Discussion
In this study of black patients with stage 2 hypertension, amlodipine/valsartan reduced MSSBP change from baseline significantly more than amlodipine alone. Also amlodipine/valsartan controlled more patients to the BP goal o 140/90 mm Hg. The BP lowering and control rates were greater in amlodipine/valsartan than with amlodipine monotherapy both before and after the addition of optional, low-dose HCTZ-despite the fact that a higher proportion of participants in the amlodipine group actually received hydrochlorothiazide. In addition, the combination therapy was more effective than amlodipine in the reduction of MSSBP from baseline in many subgroups analysed, including older adults (X65 years), those with isolated systolic hypertension, overweight and obese patients, and patients with diabetes. The results of this study were consistent with the findings of a previously reported trial in a broader patient population. 21 We believe that amlodipine was a logical active comparator for amlodipine/valsartan given that amlodipine has proven to be a highly efficacious antihypertensive agent for lowering BP in blacks 15 and also because of the long-standing predilection for favoring calcium antagonists as initial therapy in black patients.
The results of this study confirm the validity of the recommendations from both JNC 7 and International Society on Hypertension in Blacks for a strong consideration of combination drug therapy in patients with BP levels that are, respectively, 15/10 and 20/10 mm Hg above goal. The rationale for their recommendations is that single drug therapy, even with the most efficacious BP-lowering drug, will leave the majority of such patients with BP levels above goal.
Our study of combination therapy with a calcium antagonist and RAS blocker compared to monotherapy with a calcium antagonist, a long favored drug class for black hypertensives, is timely for several reasons. First, previous studies have reported that blacks (African-American patients) respond to diuretics and calcium channel blockers with greater average BP lowering than to blockers of the reninangiotensin aldosterone system. 3, 14, 15 Yet many blacks with hypertension have BP levels that are high enough above goal levels that average BP lowering with these single agents will result in inadequate BP lowering in the majority of patients. Second, there is an excessive prevalence of concurrent conditions-obesity, albuminuria, diabetes, CKD, other target-organ injury-that are linked to higher BP levels, all contribute to antihypertensive treatment resistance, 16, 22 and several of these conditions also justify setting lower than usual goal BP levels. Thus, there is the clear need for convenient, effective, and safe strategies for delivering more intensive pharmacological antihypertensive treatment to black hypertensives. Third, the combination of a calcium antagonist/RAS blocker is a potent, highly effective combination for lowering BP, yet until recently all such combinations contained ACE inhibitors. Angiotensin-converting enzyme inhibitors cause angioedema disproportionately in black compared to white hypertensives, 18 however, angioedema is rarely, if ever, truly attributable to angiotensin receptor blockers (ARB's) such as valsartan. Thus, the calcium antagonist/ARB combination will avoid the potentially troublesome side effect of ACEI-induced angioedema in a susceptible hypertensive population whereas likely providing very similar BP-lowering efficacy relative to the calcium antagonist/ACE inhibitor combination. Finally, the Food and Drug Administration recently approved the first ARB/CCB single-pill combination for initial antihypertensive drug therapy. This will most likely result in more utilization of combination drug treatments during routine hypertension treatment to physicians and other practitioners. The deemphasis of relative differences in BP lowering among various antihypertensive monotherapies in black hypertensives seems highly appropriate given the aforementioned considerations. Accordingly, only a minority of patients with hypertension of any race will achieve target BP levels with singledrug therapy. 23 Black hypertensives have B8-fold greater prevalence (8.5 vs o1%) of severe hypertension (4180/ 110 mm Hg compared to white individuals with hypertension. 24 Thus, we examined the impact of our two treatment strategies in participants with severe baseline SBP elevations (X180 mm Hg). In this subgroup least square mean change from baseline in MSSBP at week 12 was 50.5 (4.3) mm Hg (with the elective addition of HCTZ 12.5 mg) compared with a decrease of 41.7 (3.8) mm Hg in the amlodipine/HCTZ group (P ¼ 0.0465).
Pulse pressure reflects arterial stiffness and longitudinal epidemiological studies have shown its ability to independently predict CVD risk. [25] [26] [27] In fact, it is considered by some experts to be more important than mean BP in determining cardiovascular risk, including stroke, in middle-aged and older hypertensive adults. 28 In this study, the combination of amlodipine and valsartan produced a significantly greater lowering from baseline in mean sitting pulse pressure at week 8 than amlodipine alone in the older (X65 years) subgroup of patients. The difference in mean sitting pulse pressure between the two regimens was statistically significant for younger and older patients. However, the difference in MSSBP was numerically greater than the group of patients who were X65 years of age (8.2 mm Hg; P ¼ 0.0016) than in the group o65 years of age (2.9 mm Hg; P ¼ 0.0063). The effect observed on pulse pressure and MSSBP in this study are of particular relevance in older hypertensive patients and in patients with isolated systolic hypertension because they have the widest pulse pressures at baseline.
Microalbuminuria (urinary albumin excretion 30-300 mg per 100 ml À1 ) is more prevalent in black compared to white hypertensives. 29 Moreover, in black hypertensives microalbuminuria has been linked to higher BP, particularly SBP, as well as slower and lesser overall attainment of JNC 7 goal BP targets; and, when black hypertensives with microalbuminura attain goal BP levels, intensity of pharmacological treatment is significantly higher than in those without microalbuminuria. 30 In nondiabetic, nonhypertensive populations, microalbuminuria has been proven as an independent risk factor for CVD-renal disease including stroke 31, 32 In this study, urinary albumin excretion was reduced by 30% from baseline with amlodipine/valsartan compared to a 10% increase in the amlodipine monotherapy group. These data are consistent with observations from hypertensive patients with diabetic nephropathy (RENNAL) in that the combination of dihydropyridine calcium antagonists and an ARB lowers urinary protein excretion to a very appreciable degree. 33 Amlodipine/valsartan and amlodipine alone were generally well tolerated. The most common adverse events in both treatment groups were peripheral oedema and headache. The nonsignificantly higher incidence of peripheral oedema reported in the combination therapy group compared with monotherapy (12.6 vs 9.5%) is inconsistent with previous findings. Notably, the pooled results of two factorial design studies have shown that the overall incidence of peripheral oedema with the combination of amlodipine/valsartan was significantly lower compared with amlodipine monotherapy (5.4 vs 8.7%, respectively; P ¼ 0.014). 20 The inconsistency between studies may be due in part to the fact that peripheral oedema was reported at the discretion of the investigator and not measured directly.
In conclusion, in this study of black patients with stage 2 hypertension, combination therapy with amlodipine/valsartan lowered BP more effectively than amlodipine alone with a favorable safety profile comparable to amlodipine monotherapy. Although these patients are considered difficult to treat, and generally less responsive to renin-angiotensin aldosterone system monotherapy than CCB blockade, initiating treatment with combination CCB/ARB achieved rapid and sustained reductions in both systolic and diastolic blood pressure and enabled half of all the patients to reach the BP goal of below 140/90 mm Hg.
